News

NDV-3 is a prophylactic vaccine candidate which contains a recombinant Candida surface protein, Als3, and an adjuvant Alhydrogel. The study is designed to assess the efficacy of the

The company has started the European Phase III trials of ATX-101 in 2010 in collaboration with Intendis, Bayer HealthCare’s dermatology unit, which has licensed rights to ATX-101 outside

The trial aims to investigate the safety, tolerability and antiviral activity of INX-189 in conjunction with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment

The trial aims to evaluate the safety, tolerability and pharmacokinetics of PRC-4016 in healthy volunteers. Pronova CEO Morten Jurs said they believe PRC-4016 has an optimal profile to

The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use. Vical president and CEO Vijay Samant said Vaxfectin was discovered through

Lubrizol is a producer of ingredients and additives for personal care products and pharmaceuticals; specialty materials, as well as plastics technology and performance coatings in the form of

The randomized, placebo-controlled, double-blind study is designed to prove the concept of the use of EMA401 in PHN patients and to demonstrate its pharmacokinetic profile, tolerability, and safety.

Following the merger, the businesses were brought together under a newly-formed company, Alkermes plc, to be based in Ireland. As per the terms of the deal, Elan has

Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine. NeuroVive CEO Mikael Bronnegard